Abstract: The technology provided herein generally relates to novel fusion proteins suitable as human and/or animal vaccines against parasites or pathogens of the phylum Apicomplexa. In particular, the present disclosure relates to novel fusion proteins as a basis for vaccines against Plasmodium parasites, including P. falciparum, P. vivax, P. malariae, P. ovale and P. knowlesi. Nucleic acid molecules encoding said fusion proteins, vectors, host cells containing the nucleic acids and methods for preparation and producing such fusion proteins; antibodies induced or generated by the use of said fusion proteins or said nucleic acid molecules encoding said fusion proteins and the use of such antibodies or recombinant derivatives for passive immunotherapy; methods for producing such fusion proteins; compositions and methods for using such fusion proteins for the prevention and treatment of malaria are also encompassed by the present disclosure.

Abstract: A multi-aperture imaging device described herein includes at least one image sensor and an array of juxtaposed optical channels. Each optical channel includes optics for projecting at least one partial area of an object area on an image sensor area of the image sensor. The array includes: a housing including a wall structure facing or facing away from the image sensor, through which the optical channels pass, and a sidewall structure arranged on the wall structure, wherein the wall structure or the sidewall structure is formed including glass, ceramic, glass ceramic or a crystalline material, wherein the optics of the optical channels are arranged in the housing, and wherein the wall structure is connected to optics of the optical channels and fixes the optics with respect to one another.

Abstract: The technology provided herein relates to a novel type of recombinant protein complexes, in particular of antibody-like recombinant fusion protein complexes, hereinafter referred to as immunoassemblins (IAs), suitable as animal and human vaccines comprising a plurality of antigens or antigen domains derived from proteins preferably, but not necessarily presented on the surface of a pathogen. Nucleic acid molecules encoding said recombinant proteins, vectors, host cells containing the nucleic acids and methods for preparation and producing such proteins and protein complexes; antibodies induced or generated by the use of said vaccines or said nucleic acid molecules encoding said fusion proteins and the use of such antibodies or recombinant derivatives for passive immunotherapy.

Abstract: The technology provided herein relates to novel human antibodies against Plasmodium parasites, in particular against the malaria parasite Plasmodium falciparum. The present disclosure pertains to antibodies against apical membrane antigen 1 (AMA-1). These antibodies have high affinity e.g. to Plasmodium falciparum schizonts and merozoites, inhibit the reinvasion of merozoites into erythrocytes and thereby neutralize parasitic multiplication.

Abstract: The technology provided herein relates to novel anti-parasitic complexes, in particular recombinant fusion proteins suitable as human and/or animal drugs against a parasite of the phylum Apicomplexa, in particular against Plasmodium falciparum (P. falciparum) comprising at least one component A and at least one component B, characterized in that component A has a binding activity for cellular surface structures presented on the surface of a parasite of the phylum Apicomplexa or for parasitic antigens presented on a parasitized host cell, and component B is a compound having anti-parasitic activity.

Abstract: The technology provided herein relates to novel malaria vaccines composed of different recombinant proteins, in particular recombinant fusion proteins comprising several different Plasmodium falciparum antigens from the pre-erythrocytic, the blood, and the sexual parasite main stages. The proteins may be used in a mixture vaccine formulation to elicit protective immune responses in humans. Nucleic acid molecules encoding said recombinant proteins, vectors and host cells containing the nucleic acids and methods for preparation and producing such proteins are also disclosed, as well as antibodies induced or generated by the use of said malaria vaccines and the use of such antibodies or recombinant derivatives for passive immunotherapy.

Abstract: The present disclosure relates to novel malaria vaccines composed of different recombinant proteins, in particular recombinant fusion proteins comprising several different Plasmodium falciparum antigens from the pre-erythrocytic the blood, and the sexual parasite stages. The proteins and/or fusion proteins will be used in a mixture vaccine formulation to elicit protective immune responses in humans. Nucleic acid molecules encoding said recombinant proteins, vectors, host cells containing the nucleic acids and methods for preparation and producing such proteins; Antibodies induced or generated by the use of said malaria vaccines or said nucleic acid molecules encoding said proteins and/or fusion proteins and the use of such antibodies or recombinant derivatives for passive immunotherapy.

Abstract: The technology provided herein relates to novel human antibodies against Plasmodium parasites, in particular against the malaria parasite Plasmodium falciparum. The present disclosure pertains to antibodies against merozoite surface protein 10 (MSP10). These antibodies have high affinity e.g. to Plasmodium falciparum schizonts and merozoites, inhibit the reinvasion of merozoites into erythrocytes and thereby neutralize parasitic multiplication.

Abstract: An apparatus having an optical structure and ridges is described, wherein adhesive is arranged between the ridges and the optical structure, wherein the adhesive is effective to effect, after its annealing, a predetermined orientation of the optical structure in relation to a reference plane.

Abstract: An apparatus having an optical structure, ridges and an electrostatic actuator is described, wherein the ridges connect the optical structure to a supporting structure and the electrostatic drive is implemented to deflect the optical structure.

Abstract: An apparatus having an optical structure and ridges is described, wherein the ridges connect the optical structure to a supporting structure and wherein the optical structure is able to perform a movement in relation to a reference plane.

Abstract: An apparatus having an optical structure, ridges and an electrostatic actuator with a cantilever electrode is described, wherein the ridges connect the optical structure to a supporting structure and the electrostatic drive is implemented to deflect the optical structure.

Abstract: The technology provided herein generally relates to novel fusion proteins suitable as human and/or animal vaccines against parasites or pathogens of the phylum Apicomplexa. In particular, the present disclosure relates to novel fusion proteins as a basis for vaccines against Plasmodium parasites, including P. falciparum, P. vivax, P. malariae, P. ovale and P. knowlesi. Nucleic acid molecules encoding said fusion proteins, vectors, host cells containing the nucleic acids and methods for preparation and producing such fusion proteins; antibodies induced or generated by the use of said fusion proteins or said nucleic acid molecules encoding said fusion proteins and the use of such antibodies or recombinant derivatives for passive immunotherapy; methods for producing such fusion proteins; compositions and methods for using such fusion proteins for the prevention and treatment of malaria are also encompassed by the present disclosure.

Abstract: A device for varyingly irradiating by means of ray shaping is described. Furthermore, a method of manufacturing a structure made of a curable material by means of molding is described. In a first step of the method, a molding tool is arranged above a surface such that the curable material abuts on the surface and a molding surface, facing the surface, of the molding tool in a region between the molding tool and the surface and such that further curable material may continue to flow to the region. In a second step, the curable material is irradiated in the region in a locally varying manner such that the ray experiences ray shaping in an optical channel and such that the curable material cures at different speeds in a laterally varying manner.

Abstract: The technology provided herein relates to novel human antibodies against Plasmodium parasites, in particular against the malaria parasite Plasmodium falciparum. The present disclosure pertains to antibodies against merozoite surface protein 10 (MSP10). These antibodies have high affinity e.g. to Plasmodium falciparum schizonts and merozoites, inhibit the reinvasion of merozoites into erythrocytes and thereby neutralize parasitic multiplication.

Abstract: Immunogenic compositions, vaccines, constructions, host cells, and vectors that include or express one or more PfGAP50 antigen or fragment thereof. The vaccine may include an adjuvant, a pharmaceutically acceptable salt, an excipient, a preservative, a binder or a pharmaceutically acceptable liquid.

Abstract: A device for continuous production of an extrudate from finely divided plant material and a thermoplastic material. When viewed in an extrusion direction, first the finely divided plant material and then the thermoplastic material are fed to an extrusion device, which can be a twin-screw extruder. The fed-in materials are mixed with one another, degassed and jointly extruded from the extrusion device and thus form the extrudate, and the plant material is embedded in the thermoplastic material, wherein the plant material and the thermoplastic material are fed into the extrusion device at a common position or two directly successive positions. The thermoplastic material is plastified in a separate plastifier extruder before being fed into the extrusion device and is fed from the extruder to the extrusion device in a plastified state, and the plant material is then degassed together with the thermoplastic material.

Abstract: The invention relates to a process and a device for the continuous production of an extrudate from finely divided plant material and a thermoplastic material, in which, as viewed in the extrusion direction (E), firstly the finely divided plant material and then the thermoplastic material are fed to an extrusion device (1), which is embodied as a twin-screw extruder, the fed-in materials are mixed with one another, degassed and jointly extruded from the extrusion device thus forming the extrudate (6), and the plant material is embedded in the thermoplastic material, wherein the plant material and the thermoplastic material are fed into the extrusion device at a common position or two directly successive positions, the thermoplastic material is plastified in a separate plastifier extruder (4) before being fed into the extrusion device and is fed from said extruder to the extrusion device (1) in a plastified state, and the plant material is then degassed together with the thermoplastic material.

Abstract: A device for automating and/or controlling machine tools or production machines is disclosed. At least one computer is located remote from a machine and connected via at least one bus system with each of the other machines for unidirectional or bidirectional exchange of data and control signals. All control functions of the machine can be integrated in the at least one remote computer. This arrangement greatly simplifies the automation and/or control of machine tools or production machines.

Abstract: A method is disclosed for licensing software components and providing access authorization to software modules for industrial controllers, control systems and/or computer systems. A user is offered a license to software components and/or modules, wherein at least one software module with application software is created by the user and at least one license information is assigned to the created software module.